<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Inhibition of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> <z:mpath ids='MPATH_177'>angiogenesis</z:mpath> represents a promising new approach for the treatment of human <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>It has remained unclear, however, whether inhibition of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> <z:mpath ids='MPATH_177'>angiogenesis</z:mpath> may also result in <z:mp ids='MP_0001792'>impaired wound healing</z:mp>, a process thought to be <z:mpath ids='MPATH_177'>angiogenesis</z:mpath> dependent </plain></SENT>
<SENT sid="2" pm="."><plain>To determine the effects of the <z:mpath ids='MPATH_177'>angiogenesis</z:mpath> inhibitor vasostatin, a 180 amino acid calreticulin fragment, on wound healing at <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> inhibiting doses, full-thickness wounds were generated on the back of <z:mp ids='MP_0003815'>nude</z:mp> mice that were also injected intradermally with CA46 Burkitt <z:hpo ids='HP_0002665'>lymphoma</z:hpo> cells </plain></SENT>
<SENT sid="3" pm="."><plain>Mice were treated with daily injections of vasostatin or vehicle control at a site between the wounds and the transplanted <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> cells over 14 d </plain></SENT>
<SENT sid="4" pm="."><plain>Vasostatin potently inhibited <z:e sem="disease" ids="C0598934" disease_type="Neoplastic Process" abbrv="">tumor growth</z:e> and significantly reduced <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> <z:mpath ids='MPATH_177'>angiogenesis</z:mpath>, as measured by computer-assisted image analysis of CD31-stained <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> sections </plain></SENT>
<SENT sid="5" pm="."><plain>Moreover, vasostatin treatment resulted in an increased fraction of mature <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e>-associated blood vessels </plain></SENT>
<SENT sid="6" pm="."><plain>In contrast, no impairment of wound healing was observed in vasostatin-treated mice, despite a significantly reduced vascularity of the wound <z:mpath ids='MPATH_183'>granulation tissue</z:mpath> </plain></SENT>
<SENT sid="7" pm="."><plain>Our results reveal a different sensitivity of <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignant tumor</z:e> growth and physiologic wound healing to inhibition of <z:mpath ids='MPATH_177'>angiogenesis</z:mpath>, and they suggest that therapeutic inhibition of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> <z:mpath ids='MPATH_177'>angiogenesis</z:mpath> may be achieved without impairment of tissue repair </plain></SENT>
</text></document>